NASDAQ · Biotechnology · USD
BlossomHill Therapeutics, Inc. (BLSM) Stock Analysis
BlossomHill Therapeutics, Inc. (BLSM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
BLSM Key Statistics
As of Sep 4, 2026Trading
- Open
- $20.00
- Previous Close
- $20.02
- Day's Range
- 19.36–22.16
- 52-Week Range
- 15.25–22.16
- Volume
- 168.70K
Valuation
- Market Cap
- $640.08M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −3.75
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$60.56M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 0.00%
- Shares Outstanding
- 29.08M
Dividend and dates
- Avg Volume
- 290.72K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
BLSM Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$60.56M | — |
| 2024 | $0.00 | −$30.70M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$64.02M | −$60.56M | — |
| 2024 | $0.00 | — | −$36.40M | −$30.70M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
BLSM Valuation vs Biotechnology Median
Median of 656 stocks| Metric | BLSM | Biotechnology median | vs median |
|---|---|---|---|
| Profit margin | 0.00% | 0.00% | 0.0 pts above |
Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
YahooLifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32
BenzingaLeerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36
BenzingaBlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
YahooJP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28
BenzingaGuggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga
All 10 articles ↓Show fewer ↑
HC Wainwright & Co. Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $35
BenzingaBlossomhill Says FDA Grants Fast Track Designation To BH-30643 For Treatment Of Adult Patients With Advanced Or Metastatic EGFR C797S-Positive NSCLC After Prior Treatment With Third-Gen EGFR Tyrosine Kinase Inhibitor
BenzingaBlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
YahooBlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise
SeekingAlpha
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$138.42B
REGNRegeneron Pharmaceuticals, Inc.
$85.22B
ARGXargenx SE
$64.25B
MRNAModerna, Inc.
$58.11B
RVMDRevolution Medicines, Inc.
$45.01B
ONCBeOne Medicines AG
$40.53B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B